Merck to pay $250 million to Moderna
American pharmaceutical companies Moderna and Merck announced today an agreement to co-develop and commercialize an mRNA vaccine, currently being tested in combination with a cancer drug, to treat melanoma.
Moderna and Merck (or MSD outside North America) have been collaborating since 2016 on vaccine development against cancer.
Merck to pay $250 million to Moderna to activate the option envisaged at the beginning of their collaboration and to proceed to the next stage and – if everything develops according to expectations – to make the preparation available on the market.
After the deal was announced, Moderna’s stock jumped 11% in mid-day trading in New York.
Moderna, one of the first companies to develop an mRNA vaccine against Covid-19, believes that this technique can also be used for treatments against influenza, HIV, autoimmune diseases, cardiovascular diseases and many forms of cancer.
Results from phase 2 trials of the mRNA vaccine in combination with Keytruda to treat melanoma are expected by the end of the year.
Read the News today and get the latest news.
Follow Skai.gr on Google News and be the first to know all the news.
As a seasoned news journalist, I bring a wealth of experience to the field. I’ve worked with world-renowned news organizations, honing my skills as a writer and reporter. Currently, I write for the sports section at News Bulletin 247, where I bring a unique perspective to every story.
